| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sexual Behavior | 23 | 2022 | 320 | 5.510 |
Why?
|
| Sexual Dysfunction, Physiological | 13 | 2018 | 73 | 4.110 |
Why?
|
| Caregivers | 10 | 2025 | 176 | 3.610 |
Why?
|
| Referral and Consultation | 10 | 2021 | 354 | 3.220 |
Why?
|
| Sexual Dysfunctions, Psychological | 7 | 2022 | 36 | 2.670 |
Why?
|
| Urban Population | 8 | 2019 | 228 | 2.460 |
Why?
|
| Dementia | 5 | 2024 | 203 | 2.190 |
Why?
|
| Health Status | 13 | 2018 | 375 | 2.160 |
Why?
|
| Hypertension | 9 | 2025 | 763 | 1.990 |
Why?
|
| Health Surveys | 8 | 2011 | 242 | 1.840 |
Why?
|
| Sexuality | 9 | 2015 | 41 | 1.760 |
Why?
|
| Food Supply | 7 | 2024 | 29 | 1.700 |
Why?
|
| Prescription Drugs | 4 | 2018 | 39 | 1.670 |
Why?
|
| Poverty | 8 | 2019 | 189 | 1.670 |
Why?
|
| Female | 97 | 2025 | 47911 | 1.660 |
Why?
|
| Genital Neoplasms, Female | 5 | 2015 | 110 | 1.580 |
Why?
|
| Community Health Centers | 3 | 2019 | 116 | 1.580 |
Why?
|
| Socioeconomic Factors | 10 | 2023 | 610 | 1.550 |
Why?
|
| United States | 45 | 2024 | 7371 | 1.550 |
Why?
|
| Aging | 9 | 2010 | 742 | 1.550 |
Why?
|
| Myocardial Infarction | 6 | 2016 | 402 | 1.540 |
Why?
|
| Health Promotion | 3 | 2019 | 168 | 1.530 |
Why?
|
| Humans | 127 | 2025 | 92359 | 1.520 |
Why?
|
| Pandemics | 8 | 2023 | 807 | 1.520 |
Why?
|
| Cardiovascular Diseases | 8 | 2025 | 739 | 1.470 |
Why?
|
| Gynecology | 5 | 2022 | 129 | 1.470 |
Why?
|
| Community Health Services | 3 | 2021 | 80 | 1.420 |
Why?
|
| Primary Health Care | 7 | 2021 | 362 | 1.410 |
Why?
|
| Dietary Supplements | 3 | 2019 | 126 | 1.390 |
Why?
|
| Pharmacies | 2 | 2021 | 11 | 1.360 |
Why?
|
| Data Interpretation, Statistical | 5 | 2009 | 306 | 1.350 |
Why?
|
| Middle Aged | 61 | 2024 | 27057 | 1.340 |
Why?
|
| Chicago | 19 | 2025 | 1464 | 1.320 |
Why?
|
| Health Resources | 3 | 2019 | 80 | 1.290 |
Why?
|
| Electronic Prescribing | 3 | 2019 | 11 | 1.290 |
Why?
|
| Residence Characteristics | 9 | 2023 | 203 | 1.260 |
Why?
|
| Social Behavior | 5 | 2009 | 303 | 1.240 |
Why?
|
| Obstetrics | 3 | 2022 | 123 | 1.230 |
Why?
|
| Aged | 45 | 2024 | 19949 | 1.180 |
Why?
|
| Adult | 54 | 2025 | 27558 | 1.170 |
Why?
|
| Obesity | 5 | 2018 | 1006 | 1.130 |
Why?
|
| Aged, 80 and over | 25 | 2021 | 6919 | 1.130 |
Why?
|
| Adolescent | 28 | 2024 | 9494 | 1.080 |
Why?
|
| Male | 59 | 2025 | 43938 | 1.080 |
Why?
|
| Cross-Sectional Studies | 21 | 2023 | 1772 | 1.060 |
Why?
|
| Qualitative Research | 6 | 2020 | 326 | 1.060 |
Why?
|
| Child, Hospitalized | 2 | 2024 | 38 | 1.050 |
Why?
|
| Health Services Accessibility | 6 | 2021 | 452 | 1.040 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2025 | 276 | 1.030 |
Why?
|
| Uterine Cervical Neoplasms | 6 | 2012 | 306 | 0.920 |
Why?
|
| Young Adult | 22 | 2024 | 6627 | 0.910 |
Why?
|
| Child | 16 | 2025 | 7311 | 0.880 |
Why?
|
| Sexual Partners | 4 | 2015 | 104 | 0.870 |
Why?
|
| Postmenopause | 3 | 2019 | 102 | 0.870 |
Why?
|
| Survivors | 3 | 2015 | 199 | 0.850 |
Why?
|
| Diabetes Mellitus | 6 | 2021 | 758 | 0.850 |
Why?
|
| Healthcare Disparities | 4 | 2017 | 443 | 0.840 |
Why?
|
| Food Assistance | 2 | 2024 | 8 | 0.830 |
Why?
|
| Pregnancy, Ectopic | 2 | 2016 | 36 | 0.830 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2011 | 45 | 0.820 |
Why?
|
| Self-Management | 2 | 2020 | 43 | 0.820 |
Why?
|
| Population Health | 3 | 2019 | 33 | 0.810 |
Why?
|
| Prisoners | 1 | 2023 | 46 | 0.800 |
Why?
|
| Depression | 6 | 2023 | 526 | 0.790 |
Why?
|
| Vaginal Smears | 6 | 2017 | 70 | 0.780 |
Why?
|
| HIV Infections | 6 | 2011 | 901 | 0.780 |
Why?
|
| Medical Informatics | 3 | 2019 | 50 | 0.760 |
Why?
|
| Mass Screening | 10 | 2023 | 675 | 0.760 |
Why?
|
| Communication | 4 | 2016 | 462 | 0.750 |
Why?
|
| Electronic Health Records | 4 | 2021 | 365 | 0.740 |
Why?
|
| Sex Factors | 10 | 2018 | 1094 | 0.740 |
Why?
|
| Health Information Exchange | 1 | 2021 | 12 | 0.730 |
Why?
|
| Systems Analysis | 1 | 2021 | 17 | 0.730 |
Why?
|
| Breast Neoplasms | 5 | 2023 | 3054 | 0.720 |
Why?
|
| Vagina | 4 | 2019 | 176 | 0.720 |
Why?
|
| Community Networks | 1 | 2021 | 30 | 0.720 |
Why?
|
| Drug Utilization | 3 | 2018 | 66 | 0.710 |
Why?
|
| Surveys and Questionnaires | 14 | 2023 | 2734 | 0.700 |
Why?
|
| Antihypertensive Agents | 2 | 2013 | 260 | 0.700 |
Why?
|
| Prevalence | 9 | 2019 | 1297 | 0.700 |
Why?
|
| Violence | 3 | 2019 | 147 | 0.700 |
Why?
|
| Mental Health | 3 | 2023 | 183 | 0.690 |
Why?
|
| Educational Status | 5 | 2013 | 198 | 0.690 |
Why?
|
| Self Care | 2 | 2019 | 169 | 0.690 |
Why?
|
| Administrative Personnel | 1 | 2020 | 10 | 0.690 |
Why?
|
| Quality of Life | 9 | 2024 | 1745 | 0.690 |
Why?
|
| Patient Education as Topic | 2 | 2020 | 369 | 0.670 |
Why?
|
| Poverty Areas | 3 | 2018 | 37 | 0.670 |
Why?
|
| Estrogens | 2 | 2019 | 200 | 0.640 |
Why?
|
| Vaginal Neoplasms | 2 | 2012 | 84 | 0.640 |
Why?
|
| Hospitals, Pediatric | 2 | 2024 | 125 | 0.640 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2013 | 542 | 0.630 |
Why?
|
| Urban Health | 2 | 2016 | 55 | 0.610 |
Why?
|
| Cooperative Behavior | 2 | 2018 | 181 | 0.600 |
Why?
|
| Cities | 2 | 2016 | 52 | 0.600 |
Why?
|
| Independent Living | 1 | 2018 | 22 | 0.580 |
Why?
|
| Smoking Cessation | 2 | 2019 | 265 | 0.570 |
Why?
|
| Longitudinal Studies | 8 | 2024 | 1118 | 0.570 |
Why?
|
| Social Determinants of Health | 4 | 2019 | 103 | 0.570 |
Why?
|
| Risk Factors | 12 | 2024 | 5706 | 0.570 |
Why?
|
| Neoplasms | 6 | 2024 | 3123 | 0.570 |
Why?
|
| Interinstitutional Relations | 1 | 2018 | 30 | 0.560 |
Why?
|
| Data Collection | 4 | 2016 | 379 | 0.560 |
Why?
|
| Stress, Psychological | 1 | 2021 | 329 | 0.560 |
Why?
|
| Stakeholder Participation | 1 | 2018 | 22 | 0.560 |
Why?
|
| Body Mass Index | 4 | 2021 | 798 | 0.550 |
Why?
|
| Homicide | 1 | 2018 | 49 | 0.550 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 148 | 0.550 |
Why?
|
| Blood Pressure | 2 | 2019 | 906 | 0.550 |
Why?
|
| Vulvodynia | 2 | 2016 | 3 | 0.540 |
Why?
|
| Vaginal Diseases | 1 | 2017 | 28 | 0.540 |
Why?
|
| Pharmaceutical Services | 1 | 2017 | 10 | 0.530 |
Why?
|
| Needs Assessment | 2 | 2024 | 159 | 0.520 |
Why?
|
| City Planning | 1 | 2016 | 4 | 0.520 |
Why?
|
| Medicare | 5 | 2023 | 440 | 0.520 |
Why?
|
| Commerce | 1 | 2016 | 31 | 0.510 |
Why?
|
| Physician-Patient Relations | 5 | 2014 | 630 | 0.490 |
Why?
|
| Endometrial Neoplasms | 1 | 2018 | 212 | 0.490 |
Why?
|
| Infant | 5 | 2025 | 3206 | 0.490 |
Why?
|
| Counseling | 2 | 2014 | 171 | 0.490 |
Why?
|
| Cognitive Dysfunction | 1 | 2018 | 166 | 0.490 |
Why?
|
| Gynecological Examination | 1 | 2016 | 19 | 0.480 |
Why?
|
| Pregnancy | 8 | 2023 | 3113 | 0.480 |
Why?
|
| Interviews as Topic | 6 | 2019 | 351 | 0.460 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 401 | 0.460 |
Why?
|
| Hospitals, Urban | 1 | 2015 | 64 | 0.460 |
Why?
|
| Biomedical Research | 3 | 2019 | 410 | 0.450 |
Why?
|
| Continuity of Patient Care | 1 | 2016 | 176 | 0.440 |
Why?
|
| Pregnancy Outcome | 1 | 2016 | 265 | 0.440 |
Why?
|
| Interpersonal Relations | 3 | 2011 | 179 | 0.430 |
Why?
|
| Estradiol | 2 | 2019 | 250 | 0.430 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2005 | 122 | 0.420 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 1076 | 0.420 |
Why?
|
| Hospitalization | 3 | 2025 | 926 | 0.420 |
Why?
|
| Community Health Workers | 2 | 2021 | 37 | 0.410 |
Why?
|
| Pityriasis Rosea | 1 | 2013 | 2 | 0.410 |
Why?
|
| Nortriptyline | 1 | 2013 | 6 | 0.410 |
Why?
|
| Information Services | 1 | 2013 | 23 | 0.400 |
Why?
|
| Child, Preschool | 4 | 2025 | 3806 | 0.400 |
Why?
|
| Women's Health | 2 | 2006 | 105 | 0.400 |
Why?
|
| Community-Based Participatory Research | 2 | 2024 | 37 | 0.390 |
Why?
|
| Social Support | 5 | 2024 | 223 | 0.390 |
Why?
|
| Health Behavior | 4 | 2010 | 185 | 0.390 |
Why?
|
| Antidepressive Agents | 1 | 2013 | 111 | 0.380 |
Why?
|
| Health Literacy | 1 | 2013 | 73 | 0.380 |
Why?
|
| Maternal Welfare | 1 | 2011 | 9 | 0.370 |
Why?
|
| Health Services Research | 2 | 2024 | 138 | 0.370 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2025 | 886 | 0.360 |
Why?
|
| Focus Groups | 3 | 2021 | 186 | 0.360 |
Why?
|
| Delivery of Health Care | 8 | 2023 | 437 | 0.360 |
Why?
|
| Love | 1 | 2011 | 8 | 0.350 |
Why?
|
| Health Care Coalitions | 1 | 2011 | 9 | 0.350 |
Why?
|
| Cell Phone | 1 | 2011 | 38 | 0.350 |
Why?
|
| Papanicolaou Test | 3 | 2006 | 38 | 0.340 |
Why?
|
| Community-Institutional Relations | 1 | 2011 | 29 | 0.340 |
Why?
|
| Los Angeles | 2 | 2021 | 29 | 0.340 |
Why?
|
| Logistic Models | 6 | 2015 | 1239 | 0.340 |
Why?
|
| Registries | 2 | 2013 | 903 | 0.340 |
Why?
|
| Pharmacists | 2 | 2021 | 35 | 0.340 |
Why?
|
| Students | 1 | 2012 | 174 | 0.340 |
Why?
|
| Population Dynamics | 1 | 2011 | 142 | 0.340 |
Why?
|
| Mothers | 1 | 2011 | 149 | 0.340 |
Why?
|
| Medicaid | 4 | 2023 | 248 | 0.330 |
Why?
|
| Professional-Patient Relations | 2 | 2011 | 54 | 0.330 |
Why?
|
| Patient Discharge | 2 | 2023 | 340 | 0.320 |
Why?
|
| Insurance Coverage | 1 | 2011 | 134 | 0.320 |
Why?
|
| Sensation | 1 | 2009 | 50 | 0.300 |
Why?
|
| Nonprescription Drugs | 1 | 2008 | 16 | 0.300 |
Why?
|
| Patients | 2 | 2019 | 107 | 0.300 |
Why?
|
| Internet | 1 | 2011 | 331 | 0.300 |
Why?
|
| Papillomavirus Infections | 2 | 2009 | 274 | 0.290 |
Why?
|
| Pain | 3 | 2023 | 406 | 0.290 |
Why?
|
| Alphapapillomavirus | 1 | 2008 | 44 | 0.290 |
Why?
|
| Anxiety | 3 | 2023 | 324 | 0.290 |
Why?
|
| Sex Counseling | 1 | 2008 | 3 | 0.280 |
Why?
|
| Research | 2 | 2015 | 257 | 0.280 |
Why?
|
| Sex Education | 1 | 2008 | 11 | 0.280 |
Why?
|
| Reproductive Medicine | 1 | 2008 | 8 | 0.280 |
Why?
|
| Abortion, Induced | 2 | 2008 | 149 | 0.280 |
Why?
|
| Interdisciplinary Communication | 2 | 2013 | 132 | 0.280 |
Why?
|
| Spain | 3 | 2016 | 34 | 0.280 |
Why?
|
| Prejudice | 1 | 2008 | 49 | 0.270 |
Why?
|
| Moral Obligations | 1 | 2008 | 53 | 0.270 |
Why?
|
| Testosterone | 1 | 2009 | 273 | 0.270 |
Why?
|
| Religion | 1 | 2008 | 88 | 0.270 |
Why?
|
| Androgens | 2 | 2009 | 176 | 0.270 |
Why?
|
| C-Reactive Protein | 2 | 2023 | 203 | 0.270 |
Why?
|
| Length of Stay | 1 | 2011 | 790 | 0.270 |
Why?
|
| Alcoholism | 1 | 2009 | 185 | 0.270 |
Why?
|
| Parents | 2 | 2023 | 295 | 0.260 |
Why?
|
| Smoking | 2 | 2023 | 639 | 0.260 |
Why?
|
| Comorbidity | 5 | 2016 | 986 | 0.260 |
Why?
|
| Adolescent Behavior | 1 | 2008 | 110 | 0.260 |
Why?
|
| Teaching | 1 | 2008 | 147 | 0.260 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2007 | 133 | 0.250 |
Why?
|
| Quality Improvement | 2 | 2020 | 474 | 0.250 |
Why?
|
| Alcohol Drinking | 1 | 2009 | 278 | 0.250 |
Why?
|
| HIV Seroprevalence | 1 | 2005 | 9 | 0.240 |
Why?
|
| Zidovudine | 1 | 2005 | 16 | 0.240 |
Why?
|
| Prospective Studies | 6 | 2022 | 4474 | 0.230 |
Why?
|
| Self Report | 3 | 2016 | 307 | 0.230 |
Why?
|
| Drug Interactions | 3 | 2018 | 245 | 0.230 |
Why?
|
| Preventive Medicine | 2 | 2002 | 19 | 0.230 |
Why?
|
| Emergency Service, Hospital | 3 | 2025 | 557 | 0.230 |
Why?
|
| Health Education | 2 | 2021 | 105 | 0.220 |
Why?
|
| Vulnerable Populations | 1 | 2005 | 84 | 0.220 |
Why?
|
| Contraception | 2 | 2021 | 99 | 0.220 |
Why?
|
| Incidence | 2 | 2023 | 1661 | 0.210 |
Why?
|
| Prescription Drug Misuse | 1 | 2024 | 13 | 0.210 |
Why?
|
| Health Services Needs and Demand | 1 | 2024 | 108 | 0.210 |
Why?
|
| Friends | 1 | 2023 | 20 | 0.210 |
Why?
|
| Abortion, Legal | 1 | 2023 | 29 | 0.210 |
Why?
|
| Time Factors | 4 | 2019 | 5429 | 0.210 |
Why?
|
| Double-Blind Method | 2 | 2025 | 1754 | 0.200 |
Why?
|
| Nutrition Surveys | 3 | 2021 | 114 | 0.200 |
Why?
|
| Reproducibility of Results | 4 | 2017 | 2793 | 0.200 |
Why?
|
| Spouses | 2 | 2015 | 31 | 0.200 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2023 | 259 | 0.200 |
Why?
|
| Hospitals | 2 | 2023 | 313 | 0.200 |
Why?
|
| Motivation | 2 | 2018 | 306 | 0.200 |
Why?
|
| Anti-HIV Agents | 1 | 2005 | 177 | 0.200 |
Why?
|
| Point-of-Care Systems | 1 | 2023 | 147 | 0.190 |
Why?
|
| Illinois | 3 | 2011 | 502 | 0.190 |
Why?
|
| Attitude of Health Personnel | 2 | 2020 | 658 | 0.190 |
Why?
|
| Anemia, Sickle Cell | 1 | 2024 | 145 | 0.180 |
Why?
|
| Age Factors | 2 | 2018 | 1903 | 0.180 |
Why?
|
| Rural Population | 1 | 2022 | 150 | 0.180 |
Why?
|
| Outpatients | 1 | 2022 | 106 | 0.180 |
Why?
|
| Health Plan Implementation | 1 | 2021 | 59 | 0.180 |
Why?
|
| Private Sector | 1 | 2021 | 19 | 0.180 |
Why?
|
| Domestic Violence | 1 | 2021 | 28 | 0.180 |
Why?
|
| Police | 1 | 2021 | 25 | 0.180 |
Why?
|
| Evidence-Based Medicine | 2 | 2015 | 448 | 0.180 |
Why?
|
| Medicine | 1 | 2022 | 95 | 0.170 |
Why?
|
| Intimate Partner Violence | 1 | 2021 | 28 | 0.170 |
Why?
|
| Mastectomy | 1 | 2023 | 257 | 0.170 |
Why?
|
| Social Isolation | 1 | 2021 | 67 | 0.170 |
Why?
|
| Physicians | 1 | 2008 | 694 | 0.170 |
Why?
|
| Geography | 1 | 2021 | 234 | 0.170 |
Why?
|
| Practice Management, Medical | 1 | 2020 | 23 | 0.160 |
Why?
|
| Risk Assessment | 3 | 2019 | 2368 | 0.160 |
Why?
|
| Models, Theoretical | 1 | 2003 | 497 | 0.160 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 97 | 0.160 |
Why?
|
| Survival Rate | 2 | 2016 | 1926 | 0.160 |
Why?
|
| Insurance, Health | 1 | 2021 | 173 | 0.160 |
Why?
|
| Social Welfare | 1 | 2019 | 19 | 0.160 |
Why?
|
| Health Equity | 1 | 2022 | 98 | 0.160 |
Why?
|
| Vaginal Creams, Foams, and Jellies | 1 | 2019 | 2 | 0.160 |
Why?
|
| Comparative Effectiveness Research | 1 | 2020 | 55 | 0.160 |
Why?
|
| Menopause | 3 | 2022 | 85 | 0.160 |
Why?
|
| Inpatients | 1 | 2023 | 333 | 0.160 |
Why?
|
| Substance-Related Disorders | 1 | 2024 | 424 | 0.160 |
Why?
|
| Censuses | 2 | 2016 | 8 | 0.160 |
Why?
|
| Dyspareunia | 1 | 2019 | 22 | 0.150 |
Why?
|
| Dilatation | 1 | 2019 | 47 | 0.150 |
Why?
|
| Inventions | 1 | 2019 | 14 | 0.150 |
Why?
|
| Constriction, Pathologic | 1 | 2019 | 219 | 0.150 |
Why?
|
| Physical Abuse | 1 | 2018 | 5 | 0.140 |
Why?
|
| Cohort Studies | 4 | 2024 | 2980 | 0.140 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 2394 | 0.140 |
Why?
|
| Grounded Theory | 1 | 2018 | 7 | 0.140 |
Why?
|
| Computer Simulation | 2 | 2021 | 1112 | 0.140 |
Why?
|
| Reference Values | 2 | 2009 | 660 | 0.140 |
Why?
|
| Mammography | 1 | 2021 | 471 | 0.140 |
Why?
|
| Diet Surveys | 1 | 2017 | 20 | 0.140 |
Why?
|
| Attitude | 1 | 2018 | 129 | 0.140 |
Why?
|
| Cancer Survivors | 1 | 2018 | 78 | 0.140 |
Why?
|
| Radiation Oncology | 1 | 2019 | 123 | 0.140 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 470 | 0.130 |
Why?
|
| Maternal Mortality | 1 | 2016 | 15 | 0.130 |
Why?
|
| Drug Costs | 1 | 2017 | 68 | 0.120 |
Why?
|
| Epithelium | 1 | 2017 | 324 | 0.120 |
Why?
|
| Hospital Bed Capacity, 100 to 299 | 1 | 2015 | 1 | 0.120 |
Why?
|
| Nutrition Disorders | 1 | 2015 | 15 | 0.120 |
Why?
|
| Oncologists | 1 | 2016 | 38 | 0.120 |
Why?
|
| Schools | 2 | 2024 | 79 | 0.120 |
Why?
|
| Patient Selection | 1 | 2019 | 689 | 0.120 |
Why?
|
| Menopause, Premature | 1 | 2015 | 3 | 0.120 |
Why?
|
| Health Care Surveys | 1 | 2016 | 286 | 0.120 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 3776 | 0.120 |
Why?
|
| Physical Examination | 1 | 2016 | 151 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2012 | 619 | 0.110 |
Why?
|
| Body Image | 1 | 2015 | 81 | 0.110 |
Why?
|
| Endoscopy | 1 | 1998 | 359 | 0.110 |
Why?
|
| Epidemiologic Research Design | 2 | 2011 | 22 | 0.110 |
Why?
|
| Retrospective Studies | 3 | 2015 | 9695 | 0.110 |
Why?
|
| Masculinity | 2 | 2024 | 16 | 0.110 |
Why?
|
| Infant, Newborn | 3 | 2023 | 2506 | 0.110 |
Why?
|
| Cognition | 1 | 2018 | 603 | 0.110 |
Why?
|
| Curriculum | 1 | 1998 | 584 | 0.100 |
Why?
|
| Psychology | 2 | 2010 | 25 | 0.100 |
Why?
|
| Telephone | 1 | 2013 | 36 | 0.100 |
Why?
|
| Pregnancy Complications | 1 | 2016 | 346 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 2008 | 0.100 |
Why?
|
| Drug Eruptions | 1 | 2013 | 31 | 0.100 |
Why?
|
| Fear | 1 | 2013 | 82 | 0.100 |
Why?
|
| Congresses as Topic | 1 | 2013 | 119 | 0.090 |
Why?
|
| Social Conditions | 1 | 2011 | 8 | 0.090 |
Why?
|
| Human Rights | 1 | 2011 | 19 | 0.090 |
Why?
|
| Brazil | 1 | 2011 | 77 | 0.090 |
Why?
|
| Taste Disorders | 1 | 2011 | 9 | 0.090 |
Why?
|
| Administration, Oral | 1 | 2013 | 670 | 0.090 |
Why?
|
| American Heart Association | 1 | 2012 | 103 | 0.090 |
Why?
|
| Maternal Behavior | 1 | 2011 | 55 | 0.090 |
Why?
|
| Hospitals, Public | 1 | 2011 | 15 | 0.090 |
Why?
|
| Minority Groups | 2 | 2022 | 152 | 0.090 |
Why?
|
| Obstetric Surgical Procedures | 1 | 2011 | 10 | 0.090 |
Why?
|
| Organizational Case Studies | 1 | 2011 | 27 | 0.090 |
Why?
|
| Family Characteristics | 1 | 2011 | 49 | 0.090 |
Why?
|
| Models, Organizational | 1 | 2011 | 47 | 0.090 |
Why?
|
| Risk | 2 | 2010 | 661 | 0.090 |
Why?
|
| Patient Care Team | 1 | 2013 | 297 | 0.080 |
Why?
|
| Orgasm | 1 | 2010 | 9 | 0.080 |
Why?
|
| HIV Seronegativity | 1 | 2010 | 13 | 0.080 |
Why?
|
| HIV Seropositivity | 1 | 2010 | 52 | 0.080 |
Why?
|
| Olfaction Disorders | 1 | 2011 | 73 | 0.080 |
Why?
|
| Libido | 1 | 2010 | 9 | 0.080 |
Why?
|
| Cardiovascular Agents | 1 | 2010 | 58 | 0.080 |
Why?
|
| Poly dA-dT | 2 | 2000 | 2 | 0.080 |
Why?
|
| Medication Adherence | 1 | 2011 | 148 | 0.080 |
Why?
|
| Adaptation, Psychological | 1 | 2011 | 169 | 0.080 |
Why?
|
| Universities | 1 | 2011 | 148 | 0.080 |
Why?
|
| Life Expectancy | 1 | 2010 | 89 | 0.080 |
Why?
|
| Arousal | 1 | 2010 | 171 | 0.080 |
Why?
|
| Immunization Programs | 1 | 2009 | 24 | 0.080 |
Why?
|
| Utilization Review | 1 | 2009 | 23 | 0.080 |
Why?
|
| Social Class | 1 | 2010 | 138 | 0.080 |
Why?
|
| Sensory Thresholds | 1 | 2009 | 57 | 0.080 |
Why?
|
| Taste | 1 | 2009 | 29 | 0.080 |
Why?
|
| Candidiasis, Vulvovaginal | 1 | 2009 | 3 | 0.080 |
Why?
|
| Vaginosis, Bacterial | 1 | 2009 | 8 | 0.080 |
Why?
|
| Aspirin | 1 | 2010 | 163 | 0.080 |
Why?
|
| Cotinine | 1 | 2009 | 15 | 0.080 |
Why?
|
| Vision, Ocular | 1 | 2009 | 71 | 0.080 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2009 | 45 | 0.080 |
Why?
|
| Hearing | 1 | 2009 | 58 | 0.080 |
Why?
|
| Ovariectomy | 1 | 2009 | 86 | 0.070 |
Why?
|
| Internship and Residency | 1 | 1998 | 1087 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 2 | 2021 | 488 | 0.070 |
Why?
|
| Bias | 1 | 2009 | 137 | 0.070 |
Why?
|
| Papillomavirus Vaccines | 1 | 2009 | 57 | 0.070 |
Why?
|
| Cell Count | 1 | 2009 | 201 | 0.070 |
Why?
|
| Smell | 1 | 2009 | 115 | 0.070 |
Why?
|
| Specimen Handling | 1 | 2009 | 103 | 0.070 |
Why?
|
| Statistics as Topic | 1 | 2009 | 234 | 0.070 |
Why?
|
| Sexual Abstinence | 1 | 2008 | 10 | 0.070 |
Why?
|
| Rape | 1 | 2008 | 17 | 0.070 |
Why?
|
| Hospital Mortality | 1 | 2011 | 445 | 0.070 |
Why?
|
| Saliva | 1 | 2009 | 126 | 0.070 |
Why?
|
| Hormone Replacement Therapy | 1 | 2009 | 92 | 0.070 |
Why?
|
| Touch | 1 | 2009 | 106 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 374 | 0.070 |
Why?
|
| Safe Sex | 1 | 2008 | 24 | 0.070 |
Why?
|
| Condoms | 1 | 2008 | 39 | 0.070 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 995 | 0.070 |
Why?
|
| Ethics, Clinical | 1 | 2008 | 48 | 0.070 |
Why?
|
| Paclitaxel | 2 | 2000 | 495 | 0.070 |
Why?
|
| Coitus | 1 | 2007 | 20 | 0.070 |
Why?
|
| Reproductive Health Services | 1 | 2008 | 20 | 0.070 |
Why?
|
| Financing, Government | 1 | 2007 | 24 | 0.070 |
Why?
|
| Politics | 1 | 2007 | 51 | 0.070 |
Why?
|
| Personal Autonomy | 1 | 2008 | 117 | 0.070 |
Why?
|
| Women's Health Services | 1 | 2006 | 14 | 0.060 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 391 | 0.060 |
Why?
|
| Reproduction | 1 | 2008 | 201 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2021 | 8729 | 0.060 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2008 | 104 | 0.060 |
Why?
|
| Pregnancy, High-Risk | 1 | 2005 | 16 | 0.060 |
Why?
|
| Faith-Based Organizations | 1 | 2025 | 1 | 0.060 |
Why?
|
| Self Disclosure | 1 | 2005 | 32 | 0.060 |
Why?
|
| Ethics, Medical | 1 | 2008 | 308 | 0.060 |
Why?
|
| Epithelial Cells | 1 | 2009 | 702 | 0.060 |
Why?
|
| DNA | 2 | 2000 | 1314 | 0.060 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 1043 | 0.060 |
Why?
|
| Social Norms | 1 | 2024 | 14 | 0.050 |
Why?
|
| Genotype | 1 | 2008 | 1865 | 0.050 |
Why?
|
| Confidentiality | 1 | 2024 | 80 | 0.050 |
Why?
|
| Polydeoxyribonucleotides | 2 | 2000 | 5 | 0.050 |
Why?
|
| Testis | 1 | 2003 | 152 | 0.050 |
Why?
|
| Smokers | 1 | 2023 | 50 | 0.050 |
Why?
|
| Southeastern United States | 1 | 2022 | 9 | 0.050 |
Why?
|
| Housing | 1 | 2023 | 47 | 0.050 |
Why?
|
| Organ Specificity | 1 | 2003 | 282 | 0.050 |
Why?
|
| Aftercare | 1 | 2023 | 88 | 0.050 |
Why?
|
| Surface Plasmon Resonance | 2 | 2000 | 47 | 0.050 |
Why?
|
| Life Change Events | 1 | 2022 | 48 | 0.050 |
Why?
|
| Income | 1 | 2022 | 87 | 0.050 |
Why?
|
| Asia, Western | 1 | 2021 | 2 | 0.050 |
Why?
|
| Asia, Southeastern | 1 | 2021 | 16 | 0.050 |
Why?
|
| New York City | 1 | 2021 | 60 | 0.050 |
Why?
|
| Health Status Disparities | 1 | 2024 | 200 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 1761 | 0.050 |
Why?
|
| Attitude to Health | 1 | 2003 | 221 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2003 | 331 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2021 | 51 | 0.040 |
Why?
|
| San Francisco | 1 | 2021 | 25 | 0.040 |
Why?
|
| Polyribonucleotides | 1 | 2000 | 3 | 0.040 |
Why?
|
| Fluorenes | 1 | 2000 | 6 | 0.040 |
Why?
|
| Nucleosides | 1 | 2000 | 23 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2021 | 85 | 0.040 |
Why?
|
| Nucleic Acids | 1 | 2000 | 32 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2021 | 237 | 0.040 |
Why?
|
| Prostate | 1 | 2003 | 413 | 0.040 |
Why?
|
| Consumer Health Informatics | 1 | 2019 | 3 | 0.040 |
Why?
|
| Administration, Intravaginal | 1 | 2019 | 8 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2001 | 236 | 0.040 |
Why?
|
| Health Policy | 1 | 2001 | 190 | 0.040 |
Why?
|
| Bisbenzimidazole | 1 | 1998 | 1 | 0.040 |
Why?
|
| Tilorone | 1 | 1998 | 1 | 0.040 |
Why?
|
| Hematoporphyrin Derivative | 1 | 1998 | 3 | 0.040 |
Why?
|
| Intercalating Agents | 1 | 1998 | 12 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 1150 | 0.040 |
Why?
|
| Nucleic Acid Conformation | 4 | 2000 | 346 | 0.040 |
Why?
|
| Patient Preference | 1 | 2019 | 120 | 0.040 |
Why?
|
| DNA, Complementary | 1 | 1998 | 392 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 1998 | 154 | 0.030 |
Why?
|
| Cervix Mucus | 1 | 2016 | 4 | 0.030 |
Why?
|
| Perimenopause | 1 | 2016 | 5 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 173 | 0.030 |
Why?
|
| Prognosis | 2 | 2016 | 3871 | 0.030 |
Why?
|
| Circular Dichroism | 3 | 2000 | 117 | 0.030 |
Why?
|
| Models, Molecular | 4 | 2000 | 1337 | 0.030 |
Why?
|
| Psychometrics | 1 | 2016 | 335 | 0.030 |
Why?
|
| Checklist | 1 | 2015 | 68 | 0.030 |
Why?
|
| Biomarkers | 2 | 2011 | 1847 | 0.030 |
Why?
|
| Public Health | 1 | 2013 | 146 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2012 | 389 | 0.020 |
Why?
|
| Microscopy, Polarization | 2 | 2000 | 11 | 0.020 |
Why?
|
| Calorimetry, Differential Scanning | 2 | 2000 | 13 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 594 | 0.020 |
Why?
|
| Thermodynamics | 2 | 2000 | 317 | 0.020 |
Why?
|
| Linear Models | 1 | 2010 | 427 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2010 | 1512 | 0.020 |
Why?
|
| Animals | 3 | 2000 | 28050 | 0.010 |
Why?
|
| Inflammation | 1 | 2010 | 1023 | 0.010 |
Why?
|
| Poly U | 1 | 2000 | 6 | 0.010 |
Why?
|
| Spectrophotometry | 1 | 2000 | 108 | 0.010 |
Why?
|
| Chloroform | 1 | 2000 | 4 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 2000 | 176 | 0.010 |
Why?
|
| Adenine | 1 | 2000 | 89 | 0.010 |
Why?
|
| Hydrogen Bonding | 1 | 2000 | 149 | 0.010 |
Why?
|
| Polynucleotides | 1 | 2000 | 17 | 0.010 |
Why?
|
| Cattle | 1 | 2000 | 381 | 0.010 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 1999 | 43 | 0.010 |
Why?
|
| Nucleic Acid Denaturation | 1 | 1999 | 34 | 0.010 |
Why?
|
| Heating | 1 | 1999 | 17 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2000 | 180 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2000 | 316 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2000 | 432 | 0.010 |
Why?
|
| Thymus Gland | 1 | 2000 | 201 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 2000 | 196 | 0.010 |
Why?
|
| Ligands | 1 | 2000 | 457 | 0.010 |
Why?
|
| Adenosine | 1 | 2000 | 250 | 0.010 |
Why?
|